These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25935098)

  • 41. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.
    Orengo-Nania S; Landry T; Von Tress M; Silver LH; Weiner A; Davis AA;
    Am J Ophthalmol; 2001 Dec; 132(6):860-8. PubMed ID: 11730649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
    Cucherat M; Stalmans I; Rouland JF
    J Glaucoma; 2014 Jan; 23(1):e69-75. PubMed ID: 23881267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma.
    Holló G; Chiselita D; Petkova N; Cvenkel B; Liehneova I; Izgi B; Berta A; Szaflik J; Turacli E; Stewart WC
    Eur J Ophthalmol; 2006; 16(6):816-23. PubMed ID: 17191187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004.
    Feldman RM; Katz G; McMenemy M; Hubatsch DA; Realini T
    Am J Ophthalmol; 2016 May; 165():188-97. PubMed ID: 26940161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension.
    Suzuki ER; Franklin LM; da Silva LJ; Figueiredo CR; Netto JA; Batista WD
    Curr Med Res Opin; 2006 Sep; 22(9):1799-805. PubMed ID: 16968583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
    Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
    J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.
    Berdahl JP; Sarkisian SR; Ang RE; Doan LV; Kothe AC; Usner DW; Katz LJ; Navratil T;
    Drugs; 2024 Jan; 84(1):83-97. PubMed ID: 38060092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
    Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
    BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma.
    Harasymowycz PJ; Papamatheakis DG; Ennis M; Brady M; Gordon KD;
    Cornea; 2007 Jan; 26(1):34-41. PubMed ID: 17198011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety.
    Martinez-de-la-Casa JM; Castillo A; Garcia-Feijoo J; Mendez-Hernandez C; Fernandez-Vidal A; Garcia-Sanchez J
    Curr Med Res Opin; 2004 Sep; 20(9):1333-9. PubMed ID: 15383180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A short-term randomized clinical trial of daily versus alternate day use of travoprost 0.004% in the treatment of ocular hypertension.
    Khairy HA; Said-Ahmed K
    J Glaucoma; 2013 Feb; 22(2):123-6. PubMed ID: 21946548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
    Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
    Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
    King AJ; Rotchford AP
    JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%.
    Scherzer ML; Liehneova I; Negrete FJ; Schnober D
    Adv Ther; 2011 Aug; 28(8):661-70. PubMed ID: 21773673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension.
    Dixon ER; Landry T; Venkataraman S; Gustafson N; Salem C; Bradfield Y; Aljasim LA; Feldman R
    J AAPOS; 2017 Oct; 21(5):370-374.e1. PubMed ID: 28887006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study.
    Blini M; Rossi GC; Trabucchi G; Curatola MR; David A; Radaelli R; Merlo G; Ratiglia R
    Curr Med Res Opin; 2009 Jan; 25(1):57-63. PubMed ID: 19210139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.